229 related articles for article (PubMed ID: 30569112)
1. Early decrease in serum amphiregulin or vascular endothelial growth factor levels predicts sorafenib efficacy in hepatocellular carcinoma.
Godin C; Bodeau S; Saidak Z; Louandre C; François C; Barbare JC; Coriat R; Galmiche A; Sauzay C
Oncol Rep; 2019 Mar; 41(3):2041-2050. PubMed ID: 30569112
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination.
El Shorbagy S; abuTaleb F; Labib HA; Ebian H; Harb OA; Mohammed MS; Rashied HA; Elbana KA; Haggag R
J Gastrointest Cancer; 2021 Mar; 52(1):269-279. PubMed ID: 32212089
[TBL] [Abstract][Full Text] [Related]
3. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
Peng S; Wang Y; Peng H; Chen D; Shen S; Peng B; Chen M; Lencioni R; Kuang M
Hepatology; 2014 Oct; 60(4):1264-77. PubMed ID: 24849467
[TBL] [Abstract][Full Text] [Related]
4. Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.
Tsuchiya K; Asahina Y; Matsuda S; Muraoka M; Nakata T; Suzuki Y; Tamaki N; Yasui Y; Suzuki S; Hosokawa T; Nishimura T; Ueda K; Kuzuya T; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Izumi N
Cancer; 2014 Jan; 120(2):229-37. PubMed ID: 24122122
[TBL] [Abstract][Full Text] [Related]
5. Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study.
Hayashi T; Yamashita T; Terashima T; Suda T; Okada H; Asahina Y; Hayashi T; Hara Y; Nio K; Sunagozaka H; Takatori H; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S
BMC Cancer; 2017 Dec; 17(1):870. PubMed ID: 29258450
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib.
Oh CR; Kong SY; Im HS; Kim HJ; Kim MK; Yoon KA; Cho EH; Jang JH; Lee J; Kang J; Park SR; Ryoo BY
BMC Cancer; 2019 Apr; 19(1):292. PubMed ID: 30935424
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implication of serum vascular endothelial growth factor in advanced hepatocellular carcinoma staging.
Yegin EG; Siykhymbayev A; Eren F; Bekiroglu N; Ozdogan OC
Ann Hepatol; 2013; 12(6):915-25. PubMed ID: 24114822
[TBL] [Abstract][Full Text] [Related]
8. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.
Llovet JM; Peña CE; Lathia CD; Shan M; Meinhardt G; Bruix J;
Clin Cancer Res; 2012 Apr; 18(8):2290-300. PubMed ID: 22374331
[TBL] [Abstract][Full Text] [Related]
9. Vessels That Encapsulate Tumor Clusters (VETC) Pattern Is a Predictor of Sorafenib Benefit in Patients with Hepatocellular Carcinoma.
Fang JH; Xu L; Shang LR; Pan CZ; Ding J; Tang YQ; Liu H; Liu CX; Zheng JL; Zhang YJ; Zhou ZG; Xu J; Zheng L; Chen MS; Zhuang SM
Hepatology; 2019 Sep; 70(3):824-839. PubMed ID: 30506570
[TBL] [Abstract][Full Text] [Related]
10. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.
Miyahara K; Nouso K; Tomoda T; Kobayashi S; Hagihara H; Kuwaki K; Toshimori J; Onishi H; Ikeda F; Miyake Y; Nakamura S; Shiraha H; Takaki A; Yamamoto K
J Gastroenterol Hepatol; 2011 Nov; 26(11):1604-11. PubMed ID: 22011296
[TBL] [Abstract][Full Text] [Related]
11. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
Scartozzi M; Faloppi L; Svegliati Baroni G; Loretelli C; Piscaglia F; Iavarone M; Toniutto P; Fava G; De Minicis S; Mandolesi A; Bianconi M; Giampieri R; Granito A; Facchetti F; Bitetto D; Marinelli S; Venerandi L; Vavassori S; Gemini S; D'Errico A; Colombo M; Bolondi L; Bearzi I; Benedetti A; Cascinu S
Int J Cancer; 2014 Sep; 135(5):1247-56. PubMed ID: 24510746
[TBL] [Abstract][Full Text] [Related]
12. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.
Jouve JL; Lecomte T; Bouché O; Barbier E; Khemissa Akouz F; Riachi G; Nguyen Khac E; Ollivier-Hourmand I; Debette-Gratien M; Faroux R; Villing AL; Vergniol J; Ramee JF; Bronowicki JP; Seitz JF; Legoux JL; Denis J; Manfredi S; Phelip JM;
J Hepatol; 2019 Sep; 71(3):516-522. PubMed ID: 31125576
[TBL] [Abstract][Full Text] [Related]
13. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.
Lee PC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lee MH; Hou MC; Lee FY; Lin HC; Huang YH
Liver Int; 2018 Feb; 38(2):321-330. PubMed ID: 28736952
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis.
Cao G; Li X; Qin C; Li J
Med Sci Monit; 2015 Oct; 21():3144-51. PubMed ID: 26476711
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma undergoing liver transplantation.
Zhang W; Kim R; Quintini C; Hashimoto K; Fujiki M; Diago T; Eghtesad B; Miller C; Fung J; Tan A; Menon KV; Aucejo F
Liver Transpl; 2015 Jan; 21(1):101-11. PubMed ID: 25283528
[TBL] [Abstract][Full Text] [Related]
16. Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib.
Adachi T; Nouso K; Miyahara K; Oyama A; Wada N; Dohi C; Takeuchi Y; Yasunaka T; Onishi H; Ikeda F; Nakamura S; Shiraha H; Takaki A; Takabatake H; Fujioka SI; Kobashi H; Takuma Y; Iwadou S; Uematsu S; Takaguchi K; Hagihara H; Okada H;
J Gastroenterol Hepatol; 2019 Jun; 34(6):1081-1087. PubMed ID: 30402928
[TBL] [Abstract][Full Text] [Related]
17. The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib.
Caputo F; Dadduzio V; Tovoli F; Bertolini G; Cabibbo G; Cerma K; Vivaldi C; Faloppi L; Rizzato MD; Piscaglia F; Celsa C; Fornaro L; Marisi G; Conti F; Silvestris N; Silletta M; Lonardi S; Granito A; Stornello C; Massa V; Astara G; Delcuratolo S; Cascinu S; Scartozzi M; Casadei-Gardini A
PLoS One; 2020; 15(5):e0232449. PubMed ID: 32379785
[TBL] [Abstract][Full Text] [Related]
18. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.
Hong YM; Yoon KT; Hwang TH; Heo J; Woo HY; Cho M
Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1250-1255. PubMed ID: 30925530
[TBL] [Abstract][Full Text] [Related]
19. NORE1A sensitises cancer cells to sorafenib-induced apoptosis and indicates hepatocellular carcinoma prognosis.
Liu LL; Zhang MF; Pan YH; Yun JP; Zhang CZ
Tumour Biol; 2014 Mar; 35(3):1763-74. PubMed ID: 24563371
[TBL] [Abstract][Full Text] [Related]
20. Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study.
Itokawa N; Atsukawa M; Tsubota A; Okubo T; Arai T; Nakagawa A; Kondo C; Iwakiri K
Int J Clin Oncol; 2016 Aug; 21(4):676-683. PubMed ID: 26701173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
